About
About Shanghai RAAS Blood Products Co., Ltd
Shanghai RAAS Blood Products Co., Ltd., together with its subsidiaries, produces and sells blood products in China and internationally. The company offers ALBURAAS, which is albumin prepared from human plasma; GAMARAAS, a human immunoglobulin product for intravenous injections; HEMORAAS, a human coagulation factor VIII product; PROTHORAAS, a human prothrombin complex; FIBRORAAS, a human fibrinogen; FIBINGLURAAS, a fibrin sealant for humans; and THROMBIRAAS, a human thrombin product. It also provides specific immune, human tetanus immunoglobulin, human rabies immunoglobulin, human immunoglobulin, hepatitis B human immunoglobulin, and other blood products. The company exports its products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is headquartered in Shanghai, China.
Visit company website
5 years, 5 months ago
Shanghai RAAS Blood Products Co., Ltd is currently in a long term downtrend where the price is trading 6.6% below its 200 day moving average.
From a valuation standpoint, the stock is 74.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.8.
Shanghai RAAS Blood Products Co., Ltd's total revenue rose by 17.8% to $729M since the same quarter in the previous year.
Its net income has increased by 106.7% to $399M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.1% to $107M since the same quarter in the previous year.
Based on the above factors, Shanghai RAAS Blood Products Co., Ltd gets an overall score of 2/5.